Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 14/20 | 0.49 |
| ▸ | FNTB | P49356 | 14/20 | 0.49 |
| ▸ | PGGT1B | P53609 | 14/20 | 0.49 |
| ▸ | AR | P10275 | 2/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5552124 | 0.90 | FNTA (0.59) | FNTAFNTBPGGT1BTAAR1CYP19A1 | |
| SCHEMBL3518730 | 0.83 | FNTA (0.56) | FNTAFNTBPGGT1BTAAR1CYP19A1 | |
| SCHEMBL5548771 | 0.79 | FNTA (0.56) | FNTAFNTBPGGT1BARTAAR1 | |
| SCHEMBL3497955 | 0.78 | FNTA (0.80) | FNTAFNTBPGGT1B | |
| SCHEMBL8127231 | 0.76 | FNTA (0.47) | FNTAFNTBPGGT1BCYP19A1 | |
| SCHEMBL8130724 | 0.74 | TAAR1 (0.38) | FNTAFNTBPGGT1BTAAR1 | |
| SCHEMBL5553357 | 0.74 | FNTA (0.42) | FNTAFNTBPGGT1BCYP19A1 | |
| SCHEMBL3516306 | 0.74 | FNTA (0.51) | FNTAFNTBPGGT1B | |
| SCHEMBL3515256 | 0.74 | FNTA (0.46) | FNTAFNTBPGGT1BTAAR1CYP19A1 | |
| SCHEMBL3518902 | 0.73 | CYP19A1 (0.40) | FNTAFNTBPGGT1BTAAR1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000059930-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2000-10-12 | — | — | WO | claimed |
| EP-1021188-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2000-07-26 | — | — | EP | claimed |
| WO-1999017777-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1999-04-15 | — | — | WO | claimed |
| EP-2155197-A2 | TREATMENT OF LYSOSOMAL STORAGE DISEASES | Link Medicine Corporation (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008112525-A2 | TREATMENT OF LYSOSOMAL STORAGE DISEASES | LINK MEDICINE CORPORATION (US) | 2008-09-18 | — | — | WO | disclosed |
| EP-1744751-A2 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005089502-A2 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
| WO-2000059930-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2000-10-12 | — | — | WO | disclosed |
| EP-1021188-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-1999017777-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1999-04-15 | — | — | WO | disclosed |